The Patent Finder

Nsabp Foundation, Inc.

Also on record
Records under this name other than the patents Nsabp Foundation, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.

Showing 1 to 10 of 10 · Back to Nsabp Foundation, Inc.

PatentTitleStatus Expires Confidence
US 7,930,104Predicting response to chemotherapy using gene expression markers
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,067,178Gene expression markers for prediction of patient response to chemotherapy
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,868,352Predicting response to chemotherapy using gene expression markers
Formerly held
Term ended
Term ended Mar 13, 2026 · From the USPTO record
Term endedTerm ended Mar 13, 2026From the USPTO record
US 7,622,251Molecular Indicators of Breast Cancer Prognosis and Prediction of Treatment Response
Term ended
Term ended Nov 4, 2025 · High confidence
Term endedTerm ended Nov 4, 2025High confidence
US 7,526,387Expression profile algorithm and test for cancer prognosis
Formerly held
Term ended
Term ended Sep 17, 2025 · From the USPTO record
Term endedTerm ended Sep 17, 2025From the USPTO record
US 7,723,033Prediction of likelihood of cancer recurrence
Formerly held
Term ended
Term ended Jun 17, 2025 · From the USPTO record
Term endedTerm ended Jun 17, 2025From the USPTO record
US 10,619,215Prediction of likelihood of cancer recurrence
Formerly held
Term ended
Term ended Aug 13, 2024 · From the USPTO record
Term endedTerm ended Aug 13, 2024From the USPTO record
US 7,056,674Prediction of likelihood of cancer recurrence
Formerly held
Term ended
Term ended Aug 4, 2024 · From the USPTO record
Term endedTerm ended Aug 4, 2024From the USPTO record
US 7,939,261Expression profile algorithm and test for cancer prognosis
Formerly held
Term ended
Ended no later than Jun 30, 2024 · From the USPTO record
Term endedEnded no later than Jun 30, 2024From the USPTO record
US 10,166,210Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin
Lapsed on the fee record
Ended Jan 1, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jan 1, 2023From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited